摘要
目前治疗不孕症的主要手段是辅助生殖技术,人绒毛膜促性腺激素是重要的辅助生殖药物之一。第一代人绒毛膜促性腺激素药物是从妊娠期妇女尿液中提取的尿源人绒毛膜促性腺激素(Urinary human chorionic gonadotropin,u-hCG);第二代人绒毛膜促性腺激素药物是通过基因重组技术,在CHO细胞(Chinese hamster ovary cell,中国仓鼠卵巢细胞)中表达获取的重组人绒毛膜促性腺激素(Recombinant human chorionic gonadotropin,r-hCG)。相比于u-hCG,r-hCG具有纯度高,患者耐受性良好,来源不受限等优势,文章综述r-hCG制备及质量研究方法进展,并对国内h CG产品市场现状及发展趋势进行分析。
At present,the main means of treating infertility was assisted reproductive technique. The first generation of h CG drugs is u-hCG( urinary h CG),which was extracted from urine of pregnant women. The second generation,r-hCG( recombinant h CG),was expressed by Chinese hamster ovary cells engineered with gene recombination technique. Compared with u-hCG,r-hCG had high purity and patient tolerance,as well as endless resources. The development of r-hCG preparation and quality research methods was reviewed,and domestic h CG products market situation and development trend were analyzed in this paper.
作者
何荣华
高丽婷
朱红雨
许可
杨仲璠
高向东
徐明波
HE Rong-hua;GA0 Li-ting;ZHU Hong-yu;XU Ke;YANG Zhong-fan;GAO Xiang-dong;XU Ming-bo(School of Life Science and Technology,China Pharmaceutical University,Nanjing 210009,China;Beijing SL Pharmaceutical Co.,Ltd.,Beijing Engineering Research Center of Recombinant Protein and Long-acting Preparation,Beijing 100049,China)
出处
《药物生物技术》
CAS
2018年第6期542-545,共4页
Pharmaceutical Biotechnology
